Histofy, a Birmingham-based startup, has been founded to accelerate the transformation of cancer research and care with cutting-edge transparent artificial intelligence (AI) technology.
Birmingham, UK (6th February 2023) – Histofy AI, a UK-based startup, has been founded by a team of world leading experts with an accumulated 40+ years of experience in the field of digital pathology and AI. With over 250 publications in leading journals and conferences from research spanning over 20 years, the team brings their understanding of pathology and AI to spearhead the development and introduction of advanced AI tools for clinical pathology and pharmaceutical research.
Transforming Pathology with AI
Examination of pathology slides is essential in ensuring accurate diagnosis and appropriate treatment of many diseases, such as cancer. For many years, this has been done by visual inspection of the tissue with a microscope, but the digital pathology revolution means AI can be utilised to assist pathologists in delivering quicker and more accurate results – ultimately leading to better patient care.
Histofy has been launched to commercialise the AI tools the team has developed in research programmes over the past few years. This technology delivers transparent AI for deep profiling and interpretable decision-making from digitised images of pathology slides.
"This is a very exciting time for pathology as we move into an era where pathologists will be using AI to assist in analysing patient tissue samples"
Histofy Appoints CTO
Today, Histofy also announces the appointment of Dr Simon Graham as the company’s Chief Technology Officer. With a background in mathematics and computer science, Dr Graham completed his PhD in computational pathology from the world-leading Tissue Image Analytics (TIA) Centre at the University of Warwick, where he was awarded the best thesis prize in the Faculty of Science, Engineering and Medicine.
Dr Graham, Chief Technology Officer at Histofy, said: “I am excited at the prospect of placing robust AI solutions in the hands of pathology and oncology researchers and practitioners to improve patient care. We are ready to make AI accessible across a range of solutions for the digital pathology market and believe that our technology will dramatically improve the management of diseases, such as cancer”.
Prof David Snead said: “This is a very exciting time for pathology as we move into an era where pathologists will be using AI to assist in analysing patient tissue samples. Our research programme has developed some of the best and most interesting solutions. Histofy AI has been launched to take these technologies through productisation and commercialisation. Dr Simon Graham is a world leading computational pathology scientist developing this technology, so we are delighted to welcome him as our CTO.”
